Amarin Q4 revenue falls 21% on lower sales outside US, Europe

Amarin

25/02/2026 12:08

Corrects Key Details table to show Total Net Revenue, not Product Revenue, was $49.20 mln

Overview

Cardiovascular-focussed pharma firm's Q4 revenue fell 21% yr/yr

Operating expenses decreased 31% due to restructuring

Company maintained U.S. market leadership for VASCEPA

Outlook

Amarin aims for positive cash flow throughout 2026

Company continues to expand European presence through Recordati partnership

Amarin focuses on maximizing shareholder value and capital management

Result Drivers

RESTRUCTURING IMPACT - Amarin's Q4 operating expenses decreased 31% due to restructuring efforts, including cost optimization initiatives

EUROPEAN SALES TRANSITION - Decline in ROW sales due to transition to partnered sales model in Europe, impacting Q4 revenue

COST SAVINGS - Achieved $31 mln in cost savings from restructuring, contributing to improved financial performance

Company press release: ID:nGNX89tM6f

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Total Net Revenue
$49.20 mln
Q4 Operating Expenses
$29.50 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Amarin Corporation PLC is $12.00, about 22.7% below its February 24 closing price of $15.52

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)